- Clinical Interests
- Gout and pseudogout
- Rheumatoid arthritis
- Psoriatic arthritis
- Giant cell arteritis
- Sjogren's syndrome
- ANCA-associated vasculitis
- Medical Education
- MD, Yonsei University College of Medicine
- Residency, MetroWest Medical Center
- Fellowship, Barnes Jewish Hospital|Fellowship, Massachusetts General Hospital
- Foreign Languages
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- OSW - Maine
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
Dr. Hyon Choi received his rheumatology fellowship training at Massachusetts General Hospital and Harvard Medical School, and his master's and doctorate degrees in epidemiology from Harvard University. Dr. Choi has been a leading clinical rheumatologist and investigator with a primary focus on gout, rheumatoid arthritis, and psoriatic arthritis throughout his academic career, as reflected by his funding (National Institutes of Health [NIH] and industry), publications (over 200, including >60 gout-related peer-reviewed papers including those published in NEJM, JAMA, Lancet, Nat Genet, Ann Int Med, BMJ, Arch Int Med, Am J Med, Ann Rheum Dis, A&R), and reviewer activities for top journals and the NIH. The significance of Dr. Choi?s contributions has been widely accepted by the field, and his findings have been referenced by many articles as well as by the recent guidelines from the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR, 2012). His clinical and epidemiologic research has provided state-of-the-art evidence to inform the gout field, which is needed to move its guidelines from expert-consensus to an evidence-based approach.
- Research Summary
- Dr. Choi has been a leading physician investigator with primary focus on gout and other inflammatory arthritic conditions throughout his academic career. His research has been funded by the NIH, Rheumatology Research Foundation, and industry, resulting in >200 publications (including those published in NEJM, JAMA, Lancet, Nat Genet, Ann Int Med, BMJ, Ann Rheum Dis, A&R). His research findings have been referenced by many subsequent publications by others, including the recent guidelines from the European League Against Rheumatism and the American College of Rheumatology (2012). As follows, Dr. Choi's novel discoveries have provided new avenues for simple, safe, and cost-effective prevention strategies for hyperuricemia and gout, including the: 1) protective impact of dairy products; 2) hazardous impacts of sugar-sweetened soda and fructose; 3) protective impact of vitamin C; 4) protective impact of coffee; 5) protective impacts of losartan and calcium channel blockers; and 6) hazardous impacts of other classes of anti-hypertensives. Dr. Choi's research has extended to the genetics of gout and gene-environment interactions, which has led to several international collaborations and key discoveries in the field (Nat Genet 2013 and Nature2014). He has also led a multidisciplinary team for several key investigations, which have demonstrated the remarkable potential of Dual Energy Computed Tomography as an innovative tool for visualizing uric acid crystal deposits in articular and extra-articular tissue. Beyond gout research, Dr. Choi has applied innovative methodologic approaches to various rheumatic disease contexts and carried out several groundbreaking studies ,including a state-of-the-art causal analysis on the survival benefit of methotrexate (Lancet 2004).
Following the Dietary Approaches to Stop Hypertension (DASH) diet may reduce the risk of gout.
A study led by Massachusetts General Hospital investigators suggests that following a diet known to reduce the risk of hypertension and cardiovascular disease may also reduce the risk of gout.
A new Massachusetts General Hospital study finds that, while hospitalizations related to rheumatoid arthritis have dropped considerably over the past two decades, hospitalizations primarily associated with gout have increased dramatically The results reflect improved management of rheumatoid arthritis and both an increased prevalence and persistent suboptimal care of gout.
A study led by a Massachusetts General Hospital investigator finds significant racial disparities in the risk that patients being treated with the most commonly prescribed medication for gout will develop a serious, sometimes life-threatening adverse reaction, a risk that closely correlates with the frequency of a gene variant previously associated with that reaction.
55 Fruit Street
Boston, MA 02114-2696